Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

Drugs

Volumn 79, Issue 3, 2019, Pages 271-289

  Zhanel, George G ^a,f   Golden, Alyssa R ^a   Zelenitsky, Sheryl ^b   Wiebe, Karyn ^b   Lawrence, Courtney K ^b   Adam, Heather J ^a,c   Idowu, Temilolu ^b   Domalaon, Ronald ^b   Schweizer, Frank ^a,b   Zhanel, Michael A ^a   Lagacé Wiens, Philippe R S ^a,c   Walkty, Andrew J ^a,c   Noreddin, Ayman ^d   Lynch III, Joseph P ^e   Karlowsky, James A ^a,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c Diagnostic Services of Manitoba   (Canada)

^d UNIVERSITY OF SHARJAH   (United Arab Emirates)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CEFIDEROCOL; CREATINE KINASE; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; MEROPENEM; SIDEROPHORE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARBAPENEM RESISTANCE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CONSTIPATION; COUGHING; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG MECHANISM; ERYTHEMA; FEVER; FLANK PAIN; GRAM NEGATIVE BACTERIUM; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; HYPOKALEMIA; INFUSION RELATED REACTION; INSOMNIA; KIDNEY CYST; LEUKOCYTE COUNT; MEDICINAL CHEMISTRY; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; OROPHARYNX PAIN; PAIN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBITIS; PLASMA CONCENTRATION-TIME CURVE; POLYURIA; RASH; REVIEW; SIDE EFFECT; UPPER ABDOMINAL PAIN; URTICARIA; VAGINITIS; VOLUME OF DISTRIBUTION; VOMITING; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; GRAM NEGATIVE INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; CARBAPENEMS; CEFTAZIDIME; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MEROPENEM; MOLECULAR STRUCTURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIDEROPHORES;

EID: 85061031889     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-019-1055-2     Document Type: Review

References (63)

1. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55:4943–60.
2. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53:60–7.
3. Buehrle DJ, Shields RK, Clarke LG, Potoski BA, Clancy CJ, Hong Nguyen M. Carbapenem-resistant Pseudomonas aeruginosa bacteremia: risk factors for mortality and microbiologic treatment failure. Antimicrob Agents Chemother. 2017;61:e01243-16.
4. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2009;65:233–8.
5. World Health Organization. Antimicrobial resistance global report on surveillance [Internet]. 2014. Available from: http://www.who.int/drugresistance/documents/surveillancereport/en/.
6. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs. 2014;74:31–51.
7. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study). Antimicrob Agents Chemother. 2017;61:e00093-17.
8. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018;62:e01968-17.
9. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PRS, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73:159–77.
10. Carlet J, Jarlier V, Harbarth S, Voss A, Goossens H, Pittet D. Ready for a world without antibiotics? The Pensières antibiotic resistance call to action. Antimicrob Resist Infect Control. 2012;1:11.
11. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriales clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother. 2016;60:729–34.
12. Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Arjona Ferreira JC, Ariyasu M, et al. Randomized controlled trial of a novel siderophore antibiotic cefiderocol versus imipenem/cilastatin for complicated urinary tract infections caused by Gram-negative uropathogens. Lancet Infect Dis. 2018;18(12):1319–28.
13. Dunn G. Ceftizoxime and other third-generation cephalosporins: structure-activity relationships. J Antimicrob Chemother Chemother. 1982;10(Suppl C):1–10.
14. Neu HC. β-lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties. Rev Infect Dis. 1986;8:237–59.
15. Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60:7396–401.
16. Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother. 2018;62:e01454-17.
17. Ito A, Toba S, Nishikawa T, Oota M, Kanazawa S, Fukuhara N, et al. S-649266, a novel siderophore cephalosporin: binding affinity to PBP and in vitro bactericidal activity. In: 25th Eur. Congr. Clin. Microbiol. Infect. Dis.; Copenhagen. 2015.
18. Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N, et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother. 2016;60:4384–6.
19. Domalaon R, Idowu T, Zhanel GG, Schweizer F. Antibiotic hybrids: the next generation of agents and adjuvants against Gram-negative pathogens? Clin Microbiol Rev. 2018;31:e00077-17.
20. Leemans E, Fisher JF, Mobashery S. The β-lactam antibiotics: their future in the face of resistance. In: Marinelli F, Genilloud O, editors. Antimicrob. new old mol. Fight against multi-resistant Bact. Switzerland AG: Springer; 2014. p. 59–84.
21. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22:161–82.
22. Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother. 2010;54:969–76.
23. KPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother. 2016;60:4490–500.
24. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8:460–9.
25. Köhler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother. 1999;43:424–7.
26. Ito A, Nishikawa T, Matsumoto S, Fukuhara N, Nakamura R, Tsuji M, et al. S-649266, a novel siderophore cephalosporin: II. Impact of active transport via iron regulated outer membrane proteins on resistance selection. In: 54th Intersci. Conf. Antimicrob. Agents Chemother.; Washington, DC. 2014.
27. Ito A, Toba S, Nishikawa T, Kohira N, Sato T, Tsuji M, et al. Contribution of active iron transporters and binding ability to penicillin binding proteins of cefiderocol (S-649266) to its antibacterial/bactericidal activity against Klebsiella pneumoniae and Escherichia coli. In: ASM Microbe 2017; New Orleans. 2017.
28. Olofsson SK, Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis. 2007;45:S129–36.
29. Andersson DI. Improving predictions of the risk of resistance development against new and old antibiotics. Clin Microbiol Infect. 2015;21:894–8.
30. Kohira N, Nakamura R, Ito A, Nishikawa T, Ota M, Sato T, et al. Resistance acquisition studies of cefiderocol by serial passage and in vitro pharmacodynamic model under human simulated exposure. In: ASM Microbe 2018; Atlanta. 2018.
31. Tsuji M, Kazmierczak K, Hackel M, Echols R, Yamano Y, Sahm D. Cefiderocol (S-649266) susceptibility against globally isolated meropenem non-susceptible Gram-negative bacteria containing serine and metallo-carbapenemase genes. In: ASM Microbe 2018; Atlanta. 2018.
32. Yamano Y, Tsuji M, Hackel MA, Echols R, Sahm DF. In vitro activity of cefiderocol against globally collected carbapenem resistant Gram-negative bacteria including isolates resistant to ceftazidime/avibactam, ceftolozane/tazobactam and colistin: SIDERO-CR-2014/2016 study. In: 27th Eur. Congr. Clin. Microbiol. Infect. Dis.; Vienna. 2017.
33. Tsuji M, Hackel M, Yamano Y, Echols R, Sahm DF. Surveillance of cefiderocol in vitro activity against Gram-negative clinical isolates collected in Europe: SIDERO-WT-2014. In: 27th Eur. Congr. Clin. Microbiol. Infect. Dis.; Vienna. 2017.
34. Tsuji M, Hackel MA, Echols R, Yamano Y, Sahm DF. Global surveillance of cefiderocol (S-649266) against Gram-negative clinical strains collected in North America: SIDERO-WT-2014. In: ASM Microbe 2017; New Orleans. 2017.
35. Hackel M, Tsuji M, Echols R, Sahm D. In vitro antibacterial activity of cefiderocol (S-649266) against Gram-negative clinical strains collected in North America and Europe (SIDERO-WT-2014 study). In: IDWeek; New Orleans. 2016.
36. Tsuji M, Yamaguchi T, Nakamura R, Kanazawa S, Ito-Horiyama T, Sato T, et al. S-649266, a novel siderophore cephalosporin: In vitro activity against Gram-negative bacteria isolated in Japan including carbapenem resistant strains. In: IDWeek; San Diego. 2015.
37. Tsuji M, Hackel M, Echols R, Yamano Y, Sahm DF. In vitro activity of cefiderocol against globally collected carbapenem-resistant Gram-negative bacteria isolated from urinary tract source: SIDERO-CR-2014/2016. In: IDWeek; San Diego. 2017.
38. Ito A, Kohira N, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y, et al. S-649266, a novel siderophore cephalosporin: I. In vitro activity against Gram-negative bacteria including multidrug-resistant strains. In: 54th Intersci. Conf. Antimicrob. Agents Chemother; Washington, DC. 2014.
39. Tsuji M, Kohira N, Nakamura R, Sato T, Yamano Y. S-649266, a novel siderophore cephalosporin: in vitro combination effect of S-649266 and other antibiotics against Gram-negative bacteria. In: 26th Eur. Congr. Clin. Microbiol. Infect. Dis.; Amsterdam. 2016.
40. Jacobs MR, Abdelhamed AM, Good CE, Rhoads DD, Hujer KM, Hujer AM, et al. In vitro activity of cefiderocol (S-649266), a siderophore cephalosporin, against Enterobacteriaceae with defined extended-spectrum β-lactamases and carbapenemases. In: IDWeek; San Francisco. 2018.
41. Tsuji M, Hackel M, Echols R, Yamano Y, Sahm D. In vitro activity of cefiderocol against Gram-negative clinical isolates collected in North America from urinary tract source: SIDERO-WT-2014/SIDERO-WT-2015. In: IDWeek; San Diego. 2017.
42. Falagas M, Skalidis T, Vardakas K, Legakis N, Tsiplakou S, Papaioannou V, et al. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother. 2017;72:1704–8.
43. Dobias J, Dénervaud-Tendon V, Poirel L, Nordmann P. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017;36:2319–27.
44. Tsuji M, Hackel M, Yamano Y, Echols R, Sahm DF. The in vitro activity of cefiderocol, a novel siderophore cephalosporin, against a global collection of Stenotrophomonas maltophilia. In: 27th Eur. Congr. Clin. Microbiol. Infect. Dis.; Vienna. 2017.
45. Shields RK, Kline EG, Jones CE, Mettus RT, Clancy CJ, Hong Nguyen M, et al. Cefiderocol minimum inhibitory concentrations against ceftazidime-avibactam susceptible and resistant carbapenem-resistant Enterobacteriaceae. In: ASM Microbe 2018; Atlanta. 2018.
46. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. M100, 28th ed; Wayne. 2018.
47. International Organization for Standardization. ISO 20776-1:2006. Clinical laboratory testing and in vitro diagnostic test systems—susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices—part 1: reference method for testing the in vitro. 2006.
48. Ito A, Ishibashi N, Kitanishi K, Osaki H, Sato T, Tsuji M, et al. Contribution of chelating ability with iron(III) and the utilization of iron transporters through the outer membrane to the in vitro activity of cefiderocol (S-649266) against Pseudomonas aeruginosa. In: ASM Microbe 2017; New Orleans. 2017.
49. Saisho Y, Katsube T, White S, Fukase H, Shimada J. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. 2018;62:e02163-17.
50. Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C. Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol. 2017;57:584–91.
51. Katsube T, Wajima T, Ishibashi T, Arjona Ferreira JC, Echols R. Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother. 2017;61:e01381-16.
52. Kawaguchi N, Katsube T, Echols R, Wajima T. Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis. Antimicrob Agents Chemother. 2018;62:e01391-17.
53. Nakamura R, Toba S, Ito A, Tsuji M, Yamano Y, Shimada J. S-649266, a novel siderophore cephalosporin: V. Pharmacodynamic assessment in murine thigh infection models. In: 54th Intersci. Conf. Antimicrob. Agents Chemother.; Washington, DC. 2014.
54. Horiyama T, Toba S, Nakamura R, Tsuji M, Yamano Y, Shimada J. S-649266, a novel siderophore cephalosporin: VI. Magnitude of PK/PD parameter required for efficacy in murine lung infection model. In: 54th Intersci. Conf. Antimicrob. Agents Chemother.; Washington, DC. 2014.
55. Horiyama T, Toba S, Nakamura R, Tsuji M, Yamano Y, Shimada J. S-649266, a novel siderophore cephalosporin: VII. Magnitude of PK/PD parameter required for efficacy in murine thigh infection model. In: 54th Intersci. Conf. Antimicrob. Agents Chemother.; Washington, DC. 2014.
56. Ghazi IM, Monogue ML, Tsuji M, Nicolau DP. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model. Int J Antimicrob Agents. 2018;51:206–12.
57. Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolaua DP. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61:e01022-17.
58. Matsumoto S, Singley CM, Hoover J, Nakamura R, Echols R, Rittenhouse S, et al. Efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob Agents Chemother. 2017;61:e00700–17.
59. Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother. 2016;71:670–7.
60. Horiyama T, Singley CM, Nakamura R, Tsuji M, Echols R, Rittenhouse S, et al. S-649266, a novel siderophore cephalosporin: VIII. Efficacy against Pseudomonas aeruginosa and Acinetobacter baumannii in rat lung infection model with humanized exposure profile of 2 g dose with 1 h infusion. In: 54th Intersci. Conf. Antimicrob. Agents Chemother.; Washington, DC. 2014.
61. Nakamura R, Toba S, Tsuji M, Yamano Y, Shimada J. S-649266, a novel siderophore cephalosporin: IV. In vivo efficacy in various murine infection models. In: 54th Intersci. Conf. Antimicrob. Agents Chemother.; Washington, DC. 2014.
62. Ghazi IM, Monogue ML, Tsuji M, Nicolau DP. Humanized exposures of cefiderocol, a siderophore cephalosporin, display sustained in vivo activity against siderophore-resistant Pseudomonas aeruginosa. Pharmacology. 2018;101:278–84.
63. Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Arjona Ferreira JC, Ariyasu M, et al. Clinical response of cefiderocol compared with imipenem/cilastatin in the treatment of adults with complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis: results from a multicenter, double-blind, randomized study (APEKS-cUTI). In: IDWeek; San Diego. 2017.